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Alzheimer’s disease (AD) is emerging as a synapto-
pathology driven by metaplasticity. Indeed, remi-
niscent of metaplasticity, oligomeric forms of the
amyloid-b peptide (oAb) prevent induction of
long-term potentiation (LTP) via the prior activation
of GluN2B-containing NMDA receptors (NMDARs).
However, the downstream Ca2+-dependent sig-
naling molecules that mediate aberrant metaplas-
ticity are unknown. In this study, we show that
oAb promotes the activation of Ca2+/calmodulin-
dependent kinase II (CaMKII) via GluN2B-contain-
ing NMDARs. Importantly, we find that CaMKII
inhibition rescues both the LTP impairment and
the dendritic spine loss mediated by oAb. Mecha-
nistically resembling metaplasticity, oAb prevents
subsequent rounds of plasticity from inducing
CaMKII T286 autophosphorylation, as well as the
associated anchoring and accumulation of synaptic
AMPA receptors (AMPARs). Finally, prolonged oAb
treatment-induced CaMKII misactivation leads to
dendritic spine loss via the destabilization of sur-
face AMPARs. Thus, our study demonstrates that
oAb engages synaptic metaplasticity via aberrant
CaMKII activation.
INTRODUCTION
Alzheimer’s disease (AD) is emerging as a synaptopathology
driven by metaplasticity (Hulme et al., 2013; Zorumski and Izumi,
2012). In a manner reminiscent of metaplasticity events,
numerous studies have shown that oligomeric forms of the
amyloid-b peptide (oAb) prevent the induction of long-term
potentiation (LTP) via the prior activation of N-methyl-D-aspar-
tate receptors (NMDARs) (Hulme et al., 2013; Malinow, 2012).
The critical role of NMDARs inmediating the synaptotoxic effectsCell
This is an open access article under the CC BY-Nof oAb is highlighted by several studies showing that NMDAR
antagonists can fully rescue the effects of oAb (Hsieh et al.,
2006; Shankar et al., 2007). More recently, it was shown that
oAb specifically targets NMDARs containing the N-methyl-
D-aspartate receptor 2B (GluN2B) subunit, because the specific
antagonist ifenprodil was able to completely reverse the
oAb-mediated inhibition of LTP (Hu et al., 2009; Rammes et al.,
2011; Ro¨nicke et al., 2011). Given the critical role of GluN2B-con-
taining NMDARs in mediating the synaptotoxic effects of oAb, it
has become critical to elucidate the downstream Ca2+-depen-
dent signaling cascades triggering synaptotoxicity. In this study,
we investigated the role of Ca2+/calmodulin-dependent kinase II
(CaMKII) in oAb-mediated synaptotoxicity for a number of rea-
sons. First, CaMKII is the most prominent protein associated
with the GluN2B subunit, both at the structural and functional
levels (Coultrap and Bayer, 2012; Hell, 2014). Second, it is well
accepted that CaMKII is part of a core mechanism for LTP
expression (Huganir and Nicoll, 2013). The fact that oAb consis-
tently and robustly inhibits LTP suggests that it might be inter-
fering with such a core LTP mechanism. Third, CaMKII has
been recently shown to play a direct role in metaplasticity
because prior activation of CaMKII prevents the subsequent
induction of LTP (Yang et al., 2011). In addition, transgenic ani-
mals overexpressing active CaMKII present LTP deficits in a
metaplasticity-like manner (Deisseroth et al., 1995; Mayford
et al., 1995).
Using a combination of state-of-the-art microscopy and
electrophysiology, we demonstrate that oAb triggers the
activation of CaMKII in a GluN2B-dependent manner. More
importantly, we unveil a critical role of CaMKII activation
in oAb-induced LTP impairment and dendritic spine loss. In
a manner resembling synaptic metaplasticity, the oAb-medi-
ated activation of CaMKII prevents subsequent LTP-induced
T286 autophosphorylation of CaMKII, as well as the associ-
ated synaptic translocation and anchoring of synaptic
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tors (AMPARs). Our study substantiates the emerging notion
that oAb engages synaptic metaplasticity to drive pathology
at the early stages of AD.Reports 23, 3137–3145, June 12, 2018 ª 2018 The Author(s). 3137
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
AB
C D
Figure 1. oAb Activates CaMKII in a
GluN2B-Dependent Manner
(A) Sample image of a cultured hippocampal
neuron expressing the modified FRET-based
CaMKIIa sensor (left) and the lifetimes images of
the same neuron before (middle) and after (right)
incubation with oAb (0.5 mM for 30 min). Note that
oAb increased GFP lifetime (warm colors), re-
flecting a decrease in FRET because of the open-
conformation of active CaMKII. Scale bars, 20 mm
(above); 1 mm (below).
(B) Line graph displaying the time course of
CaMKII activation in dendritic spines during oAb
incubation. For controls (black line), mean ± SEM
GFP lifetime: t0 = 1.872 ns, t15 = 1.875 ns, t30 =
1.873 ns, t45 = 1.864 ns. For oAb (red line), mean ±
SEM GFP lifetime: t0 = 1.888 ns, t15 = 1.859 ns,
t30 = 2.073 ns, t45 = 2.090 ns.
(C) Bar graph showing the mean ± SEM GFP life-
time 15 min after oAb incubation. Mean ± SEM
GFP lifetime: control (Ctrl) = 1.873 ns (n = 99),
oAb = 2.073 ns (n = 89), oAb + ifenprodil = 1.784 ns
(n = 69), oAb + KN93 = 1.770 ns (n = 176), and
oAb + TTX = 2.048 ns (n = 124).
(D) Bar graph showing the mean ± SEM GFP life-
time after APP overexpression. Mean ± SEM GFP
lifetime: Ctrl = 1.793 ns (n = 1079), APP = 2.003 ns
(n = 348), APP MV = 1.761 ns (n = 348), and APP +
ifenprodil = 1.663 ns (n = 157).
***p < 0.001.RESULTS
oAb Activates CaMKII in a GluN2B-Dependent Manner
To determine the impact of oAb on the spatiotemporal dynamics
of CaMKII activation, we used the modified fluorescence reso-
nance energy transfer (FRET)-based CaMKIIa sensor previously
reported (Lee et al., 2009). Cultured hippocampal neurons
expressing the CaMKII sensor were acutely exposed to an olig-
omeric preparation of the Ab1–42 peptide (Figure S1A), and FRET
was measured using fluorescence lifetime imaging microscopy
(FRET-FLIM). We found that oAb promoted a dose-dependent
activation of CaMKII throughout the somatodendritic region
including dendritic spines, as opposed to a vehicle-only control
(Figures 1A and 1B; Figure S1B). Consistent with the proposed3138 Cell Reports 23, 3137–3145, June 12, 2018role of GluN2B-containing NMDAR in
the oAb effects, we found that CaMKII
activation was fully prevented by the
GluN2B antagonist ifenprodil (Figure 1C)
and also the CaMKII inhibitor KN93. On
the other hand, the action potential
blocker tetrodotoxin (TTX) (1 mM) did not
prevent CaMKII activation, ruling out an
indirect effect via an oAb-mediated hy-
perexcitability of neuronal circuits.
AD is triggered by the release of the Ab
peptide into the extracellular space after
proteolysis of amyloid precursor protein
(APP). To examine whether the endoge-
nous cleavage of APP and the conse-quent release of the Ab peptide was sufficient to activate
CaMKII, we coexpressed the CaMKII sensor along with APP.
We found that APP overexpression caused a robust increase
in CaMKII activity (Figure 1D). Importantly, overexpression of
the non-cleavable APP mutant M596V had no effect on CaMKII
activity, indicating that the release of the Ab peptide (and/or
other b-secretase products), and not APP itself, triggers CaMKII
activation. In line with the role of GluN2B-containing NMDAR, we
found that ifenprodil also fully prevented the APP-mediated
activation of CaMKII (Figure 1D).
We then examined the impact of oAb on CaMKII autophos-
phorylation (T286), which is usually used as a proxy of CaMKII
activation. Using western blots, we found that oAb had no effect
on CaMKII autophosphorylation at a concentration and
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Figure 2. oAb Prevents the Further cLTP-
Mediated Activation of CaMKII
(A) Representative blots against autophosphory-
lated T286 CaMKII, total CaMKII, p831 GluA1,
total GluA1, and actin.
(B) Bar graph of the mean ± SEM pCaMKII:CaMKII
ratio for the different conditions (Ctrl = 100%,
cLTP = 132.3%, oAb = 100%, and oAb + cLTP =
111.6%).
(C) Bar graph of the mean ± SEM p831GluA1:total
GluA1 for the different conditions (Ctrl = 100%,
cLTP = 139.5%, oAb = 100%, and oAb + cLTP =
144.9%).
(D) Sample images of dendritic region of a cultured
hippocampal neuron expressing CaMKII::GFP
before and after photobleaching. Scale bar, 1 mm.
The red and yellow arrows indicate the photo-
bleached dendritic spine.
(E) Normalized fluorescence recovery after pho-
tobleaching of CaMKII::GFP under control condi-
tions (black trace), after oAb preincubation (green
trace), after cLTP (blue trace), and after oAb pre-
incubation and cLTP together (red trace).
(F) Bar graph of the mean ± SEM fluorescence
recovery at the last time point recorded (3min after
photobleaching) for all the conditions (control
0.732, n = 51 spines; cLTP 0.444, n = 50 spines;
oAb preincubation, n = 50 spines; and oAb and
cLTP 0.699, n = 60 spines).
(G) Experimental scheme representing the labeling
strategy. Endogenous GluA2-containing AMPARs
were tracked using primary antibody against the
GluA2 N-terminal domain and Qdots-coupled
secondary antibody.
(H) Representative trajectories of the surface
diffusion of endogenous GluA2-containing
AMPARs in mature cultured hippocampal neurons. Note that in control conditions (but not after exposure to oAb) cLTP decreased the surface explored by
endogenous AMPARs during the recording period (30 s). Scale bar, 0.5 mm.
(I) Bar graph of the median diffusion coefficient of AMPARs (±20%–75% interquartile range [IQR]) (in mm2/sec: control 0.0236 [n = 1067]; cLTP 0.0098 [n = 459];
cLTP + oAb 0.018 [n = 277]).
***p < 0.001.incubation time similar to those used with the FRET assay
(Figures 2A and 2B). Similarly, oAb had no effect on the phos-
phorylation of S831 in the GluA1 subunit of the AMPAR, a known
CaMKII substrate. As a positive control, we confirmed that acti-
vation of NMDARs via a standard chemical LTP (cLTP) protocol
promoted strongCaMKII autophosphorylation and phosphoryla-
tion of S831 in GluA1 (Figures 2A and 2C).
In order to confirm that oAb promoted CaMKII activation inde-
pendently of T286 autophosphorylation, we applied oAb to
neurons expressing the CaMKII FRET sensor carrying a T286A
mutation. In agreement with the western blot data, we found
that oAb still promoted a robust and significant activation of
this autophosphorylation mutant (Figures S1C and S1D). In addi-
tion, we found that oAb also effectively activates CaMKII FRET
sensors carrying mutations at other post-translational modifica-
tions sites known to activate CaMKII such as oxidation (M281V),
nitrosylation (C280/289V), and glycosylation (S279A) (Figures
S1C and S1D).
Given that autophosphorylation, as well as other posttransla-
tional modifications, normally results in autonomous Ca2+-inde-
pendent CaMKII activity, we performed in vitro experiments toevaluate the effect of oAb on autonomous kinase activity. As
expected from the above experiments, we found that oAb
does not modify the levels of autonomous CaMKII activity (Fig-
ure S2). As a positive control, we confirmed that the autonomous
CaMKII activity can be increased by prior in vitro autophosphor-
ylation or phosphatase inhibitors (Figure S2).
Taken together, this set of experiments demonstrates that oAb
increases overall CaMKII activity but fails to promote CaMKII
autophosphorylation and, consequently, an increase in autono-
mous activity.
oAb Engages Metaplasticity via CaMKII
According to ametaplasticity mechanism of action, the oAb-me-
diated activation of CaMKII may prevent CaMKII activation by
subsequent plasticity-inducing stimuli. Using western blots, we
found that prior incubation with oAb (0.5 mM for 30 min)
prevented the subsequent autophosphorylation of CaMKII trig-
gered by cLTP (Figures 2A and 2B). Similarly, using the FRET
sensor, we found that both prior incubation with oAb and APP
overexpression decreased the dynamic range of cLTP-mediated
CaMKII activation (Figure S3). We then examined whether oAbCell Reports 23, 3137–3145, June 12, 2018 3139
Figure 3. CaMKII Activation Drives the
oAb-Mediated Deficits in LTP
(A) The CaMKII inhibitor KN93 (0.5 mM; blue trace)
completely rescued the oAb-mediated impairment
in LTP in acute hippocampal slices (red trace).
(B) Bar graph of the mean ± SEM fEPSP slope
between 70 and 80 min after HFS used for statis-
tical comparisons (fEPSP slope [%]: Ctrl = 162.7%
[n = 7], oAb = 125.1% [n = 14], and oAb + KN93 =
159.0% [n = 8]).
(C) The CaMKII inhibitor tatCN21 (5 mM; green
trace) completely rescued the oAb-mediated
impairment in LTP in acute hippocampal slices (red
trace).
(D) Bar graph of the mean ± SEM fEPSP slope
between 70 and 80 min after HFS used for statis-
tical comparisons (fEPSP slope [%]: Ctrl = 237.2%
[n = 14], oAb = 123.5% [n = 9], and oAb + tatCN21 =
234.7% [n = 10]). Note that Ctrl corresponds to
pooled values from two control groups: vehicle
(n = 6) and tatCN21-only (n = 8) pre-treated slices.
*p < 0.05; **p < 0.01.might also prevent other activity-dependent features of CaMKII
that are known to be critical for the induction of LTP such as
its synaptic translocation and the anchoring of synaptic AMPARs
(Coultrap and Bayer, 2012; Hell, 2014; Lisman et al., 2012;
Opazo et al., 2010). First, we found that oAb pre-incubation
prevented the cLTP-mediated immobilization of CaMKII at den-
dritic spines (Figures 2D–2F). Second, we found that oAb pre-in-
cubation also blocked the cLTP-mediated diffusional trapping of
AMPARs (Figures 2G–2I). Together, these findings demonstrate
that the oAb-mediated activation of CaMKII prevents subse-
quent rounds of plasticity from engaging activity-dependent
features of CaMKII that are critical for LTP.
CaMKII Activation Drives oAb-Mediated Synaptotoxicity
Does CaMKII activation contribute to the detrimental effects of
oAb on LTP? Given that CaMKII is part of the core mechanism3140 Cell Reports 23, 3137–3145, June 12, 2018for LTP induction (Huganir and Nicoll,
2013), we examined whether preventing
the oAb-mediated activation of CaMKII
(and thus restoring CaMKII activity to
basal levels) might be sufficient to rescue
the LTP impairment. To that end, we pre-
incubated acute hippocampal slices with
oAb (0.5 mM) alone or in the presence of
CaMKII inhibitors, either KN93 (1 mM) or
tatCN21 (5 mM). Importantly, to allow the
proper activation of CaMKII during LTP,
we washed out CaMKII inhibitors 40–
45 min before the LTP-inducing protocol.
As shown in Figure 3, we found that both
KN93 and tatCN21completely rescued
the oAb-mediated inhibition of LTP.
Importantly, we found that pre-incubation
with oAbwith or without KN93 or tatCN21
has no impact on input-output curves
(fiber volley amplitude versus field excit-atory postsynaptic potential [fEPSP] slope; Figure S4). Together
with previous experiments showing that co-incubation with ifen-
prodil can also rescue LTP (Hu et al., 2009; Rammes et al., 2011;
Ro¨nicke et al., 2011), our findings suggest that oAb activates the
canonical GluN2B-CaMKII pathway to prevent the subsequent
induction of LTP in a manner reminiscent of the metaplasticity-
mediated inhibition of LTP (Yang et al., 2011).
Although at first oAb impacts the ability of synapses to un-
dergo plasticity, a long-term exposure ultimately leads to the
loss of dendritic spines (Um et al., 2012), the preferred site of
excitatory synapses. We thus examined whether oAb-mediated
CaMKII activation might also contribute to dendritic spine loss.
To this end, we used confocal microscopy to image the same
neuron before and after a 5-hr-long exposure to oAb, a time point
known to be sufficient to induce significant spine loss (Um et al.,
2012). Although dendritic spine density remained constant
AB
Figure 4. CaMKII Activation Drives the oAb-Mediated Dendritic
Spine Loss
(A) Sample images of dendritic regions from hippocampal neurons over-
expressing the synaptic marker Homer1c::DsRed. Note that a prolonged
incubation with oAb (0.5 mM for 5 hr) promoted spine loss (yellow arrowheads)
that was blocked by both the GluN2B-antagonist ifenprodil and the CaMKII
inhibitors KN93 and tatCN21. Scale bar, 5 mm.
(B) Bar graph of the mean ± SEM survival fraction after oAb incubation. Ctrl =
102.5% (n = 4 neurons), oAb= 80% (n = 15 neurons), oAb+ ifenprodil = 102.5%
(n = 4 neurons), oAb + KN93 = 100.5% (n = 7 neurons), oAb + KN92 = 75.6%
(n = 8 neurons), and oAb + tatCN21 = 99.7% (n = 9 neurons).
***p < 0.001.during control conditions (vehicle, 5 hr), a prolonged incubation
with oAb leads to a significant loss in dendritic spines in a
GluN2B-dependent manner (Figure 4). To test the role of
oAb-mediated CaMKII activation in spine loss, we co-incubated
oAb and either KN93 or tatCN21, and found that both CaMKII in-
hibitors (but not the inactive analog KN92) completely preventeddendritic spine loss (Figure 4). Taken together, these findings
demonstrate that CaMKII activation contributes to oAb-medi-
ated synaptotoxicity at the functional and structural levels.
CaMKII Metaplasticity Leads to AMPAR Destabilization
and Spine Loss
How does CaMKII metaplasticity lead to dendritic spine loss?
Given that oAb interferes with the normal functioning of CaMKII,
it is likely that oAb precludes CaMKII from anchoring and stabi-
lizing AMPARs, one of its most critical synaptic functions (Coul-
trap and Bayer, 2012; Hell, 2014; Lisman et al., 2012; Opazo
et al., 2010). Because AMPAR content is strongly correlated to
dendritic spine structure (Matsuzaki et al., 2004), we hypothe-
sized that long-term exposure to oAb leads to the destabilization
and escape of synaptic AMPARs and, consequently, to the
collapse of dendritic spines. In order to start testing this hypoth-
esis, we first overexpressed APP and tracked the surface
mobility of synaptic AMPARs using single-particle QDot
tracking. As shown in Figures 5A–5C, we found that APP trig-
gered a dramatic destabilization of synaptic AMPARs as evi-
denced by their enhanced diffusion coefficient and decreased
immobile fraction. Importantly, we found that the non-cleavable
APP (M596V) had no effect on AMPAR diffusion (Figure 5C), sug-
gesting that the release of the Ab peptide, rather than APP itself,
triggered AMPAR destabilization. In agreement with the role of
released Ab, we found that non-transfected neurons within the
same field of view (80 3 80 mm) of APP-expressing neurons
also presented an increased destabilization of AMPARs (Fig-
ure 5D). Consistent with the metaplasticity model, we found
that both the general NMDAR antagonist 2-amino-5-phospho-
nopentanoic acid (AP5) and ifenprodil prevented AMPAR desta-
bilization (Figure 5E). To investigate the causal role of CaMKII
misactivation in AMPAR destabilization, we co-expressed APP
along with the kinase-dead CaMKII mutant K42R. As shown in
Figure 5F, we found that CaMKII K42R rescued the effects of
APP expression in AMPAR surface diffusion. Similarly, we found
that the CaMKII inhibitor tatCN21 also prevented AMPAR
destabilization. Together, these findings underlie the causal
link between prolonged CaMKII misactivation and AMPAR
destabilization.
It is widely accepted that AMPARs synaptic content and
dendritic spine size go hand in hand (Matsuzaki et al., 2004).
Because a 2-hr oAb incubation time was sufficient to destabilize
AMPARs (Figure S5), which preceded dendritic spine loss (5 hr),
we explored the possibility that these events might be causally
related. First, we reasoned that if AMPAR destabilization is
driving spine loss, then artificially destabilizing AMPARs might
worsen the effects of oAb on spines loss. We tested this hypoth-
esis by pre-incubating neurons with a recently described
peptide-based ligand that destabilizes endogenous AMPARs
by disrupting the interaction between the AMPARs auxiliary
subunit Stargazin and PSD95 (STGpep) (Sainlos et al., 2011). As
shown in Figures 5G and 5H, we found that indeed pre-incuba-
tion with STGpep exacerbated oAb-mediated spine loss. Lastly,
in order to establish a causal relationship between AMPAR
destabilization and spine loss, we prevented AMPAR destabili-
zation by specifically crosslinking GluA2-containing AMPARs
via antibodies against their extracellular N-terminal domainsCell Reports 23, 3137–3145, June 12, 2018 3141
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Figure 5. oAb Leads to AMPAR Destabiliza-
tion and Dendritic Spine Loss
(A) Schematic representation of the experimental
manipulation. Cultured hippocampal neurons
were transfected with the amyloid precursor
protein (APP), and the lateral diffusion of endog-
enous AMPARs was evaluated after 1–2 days
using a primary antibody against the GluA2
N-terminal domain and Qdots-coupled secondary
antibody.
(B) Representative trajectories of the surface
diffusion of endogenous GluA2-containing
AMPARs. Note that APP overexpression
dramatically increased the surface explored by
AMPARs during the recording period (30 s).
Scale bar, 1 mm.
(C) APP overexpression strongly increases the
mobility of endogenous AMPARs. Bar graph of the
median diffusion coefficient of endogenous
AMPARs (±20%–75% interquartile range [IQR])
(median diffusion in mm2/sec: control 0.0411
[n = 1840]; APP 0.140 [n = 1470]; APP M596V
0.056 [n = 929]).
(D) APP overexpression increases the mobility of
neighboring non-transfected neurons within the
same field of view of APP-overexpressing neurons
(median diffusion in mm2/sec: control 0.0411
[n = 1,840]; neighboring non-transfected neurons
[field APP] 0.1195 [n = 555]).
(E) AMPAR destabilization requires NMDAR ac-
tivity (median diffusion in mm2/sec: control 0.074
[n = 380]; APP 0.2334 [n = 633]; APP + AP5 0.0483
[n = 448]; APP + ifenprodil 0.042 [n = 750]).
(F) APP overexpression increases the mobility of
AMPAR in a CaMKII-dependent manner (median
diffusion in mm2/sec: control 0.074 [n = 4976];
APP 0.1141 [n = 6359]; APP + CaMKII K42R
0.0744 [n = 7,945]; APP + tatCN21 0.0352
[n = 638]).
(G) Sample images of dendritic regions from hip-
pocampal neurons overexpressing the synaptic
marker Homer1c::DsRed. Note that a prolonged
incubation with oAb (0.5 mM for 5 hr) promoted
spine loss (yellow arrowheads) that was fully rescued by the prior immobilization of AMPARs and exacerbated by prior destabilization of AMPARs. Scale bar,
5 mm.
(H) Bar graph of the mean ± SEM survival fraction 5 hr after oAb incubation for all conditions. oAb = 82% (n = 7 neurons), oAb + STGpep = 60.2% (n = 5 neurons),
and oAb + crosslinking = 100.4% (n = 9 neurons).
***p < 0.001.prior to oAb incubation (Heine et al., 2008). As shown in Figures
5G and 5H, AMPAR crosslinking was sufficient to completely
prevent the spine lossmediated by oAb. Together, these findings
support the hypothesis that oAb prevents CaMKII from serving
its critical role on AMPAR anchoring, leading to their synaptic
escape and ultimately to dendritic spine loss.
DISCUSSION
In this study, we provide mechanistic insight for a metaplasticity
model of oAb action. In the same way that a subthreshold activa-
tion of GluN2B-containing NMDAR and CaMKII prevents the
subsequent induction of LTP during metaplasticity (Yang et al.,
2011), we found that oAb engaged the same pathway to drive
impairment of LTP and spine loss. In accordance with a meta-3142 Cell Reports 23, 3137–3145, June 12, 2018plasticity mechanism of action, oAb prevented the further T286
autophosphorylation of CaMKII, its synaptic translocation, and
the functional anchoring of AMPARs, all critical steps in the
strengthening of synaptic transmission (Coultrap and Bayer,
2012; Hell, 2014; Lisman et al., 2012). In line with ametaplasticity
mechanism of action, we found that preventing the oAb-medi-
ated activation of CaMKII was sufficient to rescue LTP.
Although our findings are consistent with the well-docu-
mented coupling between GluN2B and CaMKII, they are at
odds with previous studies suggesting that oAb inhibits rather
than activates CaMKII (Gu et al., 2009; Townsend et al., 2007;
Zhao et al., 2004). We found that the reason behind these
discrepancies resides on the different approaches used to mea-
sure CaMKII activation. Although in this study we used a highly
sensitive FRET approach to measure ‘‘total’’ CaMKII activity,
all previous studies usedwestern blots with an antibody directed
against CaMKII autophosphorylation as a proxy of CaMKII activ-
ity. Because CaMKII autophosphorylation contributes very little
to the overall maximal levels of CaMKII activity (Coultrap et al.,
2012; Otmakhov et al., 2015), the oAb-mediated activation of
‘‘total’’ CaMKII activation reported here was not detected. As
before, we were unable to detect induction of CaMKII autophos-
phorylation using western blots or autonomous Ca2+-indepen-
dent activity using in vitro kinase assays at concentrations and
incubation times similar to those used with the FRET assay.
Besides this discrepancy, this and previous studies converge
on the notion that oAb prevents the activation of CaMKII by
further rounds of plasticity.
While acute exposure to oAb impacts the ability of synapses
to undergo plasticity, the long-term exposure ultimately leads
to the loss of dendritic spines. Our current work and previous
studies suggest that oAb also promotes dendritic spine loss
via a metaplasticity mechanism. First, it has been shown that
NMDAR antagonists are sufficient to rescue the dendritic spine
loss triggered by oAb (Shankar et al., 2007; Um et al., 2012).
Second, in the current study we show that two mechanistically
distinct CaMKII inhibitors fully rescue dendritic spine loss. How
does CaMKII activation trigger dendritic spine loss? In accor-
dance with a metaplasticity mechanism, it is likely that the
oAb-mediated activation of CaMKII precludes the physiolog-
ical activation of CaMKII occurring under resting conditions.
As we previously showed, interfering with the normal activation
of CaMKII for prolonged periods of time leads to the destabili-
zation and escape of synaptic AMPARs (Opazo et al., 2010).
Consistent with this hypothesis, we found that APP overex-
pression leads to the surface destabilization of AMPARs in
an NMDAR- and CaMKII-dependent manner. More impor-
tantly, we found that preventing AMPAR destabilization using
a crosslinking approach was sufficient to rescue dendritic
spine loss. Although these results identify a causal relationship
between AMPAR destabilization and dendritic spine loss, the
underlying mechanism remains to be identified. In addition,
these findings are in agreement with previous studies showing
that oAb drives synaptotoxicity by promoting AMPAR endocy-
tosis (Hsieh et al., 2006). Because the endocytic machinery is
located at extrasynaptic sites (Ra´cz et al., 2004), it is likely
that destabilized AMPARs escape the synapse prior to under-
going endocytosis.
Although our results suggest that the oAb-mediated activation
of CaMKII triggers synaptotoxicity simply by preventing further
CaMKII activation, we cannot rule out the possibility that oAb-ac-
tivated CaMKII might phosphorylate off-target substrates such
as the microtubule-associated protein Tau (Amar et al., 2017;
Steiner et al., 1990; Yoshimura et al., 2003), which in turn leads
to synaptotoxicity (Roberson et al., 2007). Regardless of whether
the oAb-mediated activation of CaMKII drives synaptotoxicity
directly (via off-target phosphorylation) or indirectly (by prevent-
ing further CaMKII activation), our finding showing that AMPAR
crosslinking fully rescued dendritic spine loss suggests that
either mechanism should eventually lead to the surface destabi-
lization of AMPARs.
Taken together, our study provides mechanistic insights into
the emerging view of oAb synaptotoxicity as an NMDAR-depen-dent metaplasticity phenomenon. Our current study demon-
strates that CaMKII is downstream of NMDAR-dependent syn-
aptotoxicity and suggests that CaMKII inhibition might also
prove beneficial as a therapeutic agent for AD (Ghosh and Giese,
2015). However, as in the case of NMDAR, it will be first
necessary to develop inhibitors that selectively prevent the
oAb-mediated activation of CaMKII and not the physiological
CaMKII activation critical for learning and memory.
In general, the emerging view of oAb synaptotoxicity as a
metaplasticity phenomenon raises the possibility that our current
understanding of synaptic metaplasticity might shed light into
the mechanisms underlying AD (Hulme et al., 2013).
EXPERIMENTAL PROCEDURES
Cultures of Sprague-Dawley rat hippocampal neurons were prepared from
embryonic day 18 (E18) Sprague-Dawley rat embryos of either sex. Animals
were used according to the guidelines of the University of Bordeaux/ Centre
national de la recherche scientifique (CNRS) Animal Care and Use
Committee.
Primary Neuronal Cultures and Transfection
Banker cultures of hippocampal neurons from E18 Sprague-Dawley rat
embryos of either sex were prepared as described previously (Penn et al.,
2017). Neurons (10–12 days in vitro [DIV]) were transfected using Effectene
as per the manufacturer’s instructions.
Oligomeric Preparation of the Ab1–42 Peptide
oAb was generated as in Ro¨nicke et al. (2011). The lyophilized Ab1–42 peptide
from Biochem (catalog number [Cat. #] H-1368) was dissolved in
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma, St. Louis, MO, USA) and ali-
quoted before removing HFIP. oAbwas obtained by incubating at 4C for 24 hr
in F12 medium. The quality of the oligomer preparation was controlled with
western blots against the amyloid-b peptide (6E10; Covance, CA, USA).
Western Blots
Western blots and cLTP experiments were prepared as described previously
(Penn et al., 2017). Cultured hippocampal neurons at DIV 14 were treated
either with vehicle or 1 mM oAb diluted in Tyrode’s buffer during 30 min. Neu-
rons were then treated with the cLTP protocol (200 mMglycine, 30 mMbicucul-
line in Tyrode’s buffer 0 Magnesium) for 5 min. Neuronal homogenates were
then western blotted against GluA1 (clone N355/1; NeuroMab), GluA1 Phos-
pho Ser 831 (Cat. #04-823; Millipore), CamKII G-1 (Cat. #sc-5306; Santa
Cruz), and Phospho CamKII T286 (Cat. #ab5683; Abcam).
Frequency Domain-Based FRET-FLIM
Experiments were performed on an inverted Leica DMI6000B (LeicaMicrosys-
tem) spinning disk microscope and using the LIFA frequency domain lifetime
attachment (Lambert Instruments; Roden, the Netherlands) and the LI-FLIM
software. Cells were excited using a sinusoidally modulated 1-W 478-nm
light-emitting diode (LED) under wide-field illumination. Lifetimes were cali-
brated using a 1 mM saline solution of fluorescein (pH 10; 4.00 ns).
Fluorescence Recovery after Photobleaching
The fluorescence recovery after photobleaching (FRAP) experiments were
performed in a spinning diskmicroscope Leica DMI6000 (LeicaMicrosystems)
equipped with a confocal Scanner Unit CSU-X1 (Yokogawa Electric Corpora-
tion, Tokyo, Japan). Diffraction limited regions on neurons expressing CaMKII-
GFP were photobleached for 5 ms with the 488-nm laser. Recovery from
photobleaching was monitored by 45 consecutive acquisitions at three
different rates (each 0.5 s during 10 s, each 2 s during 20 s, and each 10 s
during 180 s in time-lapsemode). Acquisitions and image corrections for back-
ground noise and continuous photobleaching were done using theMetaMorph
software (Molecular Devices, Sunnyvale, CA, USA).Cell Reports 23, 3137–3145, June 12, 2018 3143
AMPAR Labeling and Synaptic Live Staining
GluA2 labeling was performed in two steps. First, neurons were incubated for
10 min with a GluA2 antibody (1:200, MAB387; Chemicon). Second, neurons
were incubated for 5 min with Quantum dots (QDs) 655 Goat F(ab0)2 anti-
mouse IgG Conjugate (H+L) from Invitrogen Corporation. Synapses were
labeled by transfection with Homer1C::GFP.
Single-Molecule Optical Microscopy
QDs and Homer1C-GFP signals were detected by using a mercury lamp (for
QDs: excitation filter 560RDF55 or 460BP40 and emission filters 655WB20
or 655WB40). Fluorescent images from QDs were obtained with an integration
time of 50mswith up to 1,200 consecutive frames. Signals were recorded with
a back-illuminated thinned CCD97 camera (Photometrics Cascade 512B;
Roper Scientific).
AMPAR Tracking and Analysis
The tracking of single QDs was performed with homemade software based on
MATLAB (MathWorks, Natick, MA, USA). Owning to the random blinking events
of the QDs, sub-trajectories of the same receptor were reconnected based
on maximal position changes between consecutive frames (2–3 pixels;
0.32–0.48 mm) and blinking rates (maximal dark periods of 25 frames; 1.25 s).
Diffusion coefficients were calculated by a linear fit of the first 4–8 points of the
mean-square displacement (MSD) plots versus time. The QDs were considered
synaptic if colocalized with Homer1C dendritic clusters for at least five frames.
GluR2-AMPARs Crosslinking
For crosslinking with GluR2-containing AMPARs, neurons were pre-incubated
with the commercial monoclonal antibody against GluA2 (MAB387; Chemicon)
for 10 min followed by an incubation with the secondary AB for 10 min.
CaMKII Activity Assays in Neuronal Extracts
Primary neuronal cultures (800,000 cells/60-mm plate) were pre-treated with
either oAb (0.5 mM for 30min) or vehicle. Neuronal extracts were then assessed
for CaMKII activity via phosphate incorporation into the AC3 peptide sub-
strates as previously described (Coultrap et al., 2012).
Slice Preparation and Electrophysiology
Standard techniques were used to prepare slices (350 mm thick) from the
hippocampus of ketamine/xylazine anesthetized C57BL/6 mice (male,
2–3 months old). Slices were incubated with either vehicle, oAb (0.5 mM),
oAb (0.5 mM) + KN93 (1 mM), oAb (0.5 mM) + tatCN21 (5 mM), or tatCN21 alone
(5 mM) for 2.5–3 hr in an ‘‘incubation chamber’’ before transferring the slice to
the electrophysiology setup. After transfer, slices were allowed to wash out for
around 45 min before LTP induction (1 high frequency stimulation [HFS] train;
100 pulses at 100-Hz stimulation). Incubation and recording were done at
room temperature (RT).
Statistics
Unless stated otherwise, data values are given asmean ±SEM. Comparison of
the means of two independent samples were made with either two-tailed
Welch’s t test (parametric) or Mann-Whitney test (non-parametric) using Prism
(GraphPad, San Diego, CA, USA). To compare the means of more than two
independent samples, we used one-way ANOVA test. When used in reporting
statistical results, asterisks denote the following significance levels: *p < 0.05;
**p < 0.01; ***p < 0.001.
SUPPLEMENTAL INFORMATION
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